drugset / Trial / NCT00435760

Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT00435760

Phase 3 Completed 115 enrolled AstraZeneca
RandomizedCrossoverDouble-blindTreatment

Summary

This trial evaluates the rate of onset of bronchodilator action of aclidinium bromide compared to placebo and tiotropium in patients with severe COPD after a single dose treatment.

Timeline

Start
2007-02
Primary completion
2007-08
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Aclidinium Small molecule 200 ug Inhaled
Comparator Tiotropium Other / unclassified 18 ug Inhaled